A means of assessing abuse liability of experimental drugs in man using MRI methods and evaluating and mitigating abuse risk of novel Mechanisms-of-Action.
Assessment of abuse potential of experimental drugs that engage with novel Mechanisms of Action is required as part of their development. The FDA strongly encourages industry to pay more attention to the risk for drug abuse in experimental drugs to avoid future non-medical use.
Today, a variety of preclinical animal models for drug dependence and abuse exist albeit with varying translational properties. Because of this, innovative drug development faces a significant risk of choosing a suboptimal animal model, dosing and administration regime.
For more information, please contact:
Drug target discovery in neuroscience is increasingly relying on human samples to generate meaningful data that translates into actionable strategies. Open access to well-characterized brain tissue of high quality is crucial to obtain these insights and is the goal of the Netherlands Brain Bank. Click here to download the information sheet on this collaboration opportunity […]
The team of prof. Astrid Groot from the UvA Institute for Biodiversity and Ecosystem Dynamics (IBED) are looking for a financial sponsor which can help close the funding gap or a organization who is interested in a partnership. Aim is for finding a sustainable control strategy to address to the fall army worm pest in […]
HepaRG cells outperform all other proliferative sources of human hepatocytes in liver functions. Now we modified the HepaRG cell line by stable lentiviral overexpression of the constitutive androstane receptor (CAR), a regulator of e.g. detoxification and energy metabolism, which has the following advantages: High liver functionality & increased mitochondrial energy metabolism in monolayer, particularly in […]